Itau Unibanco Holding S.A.’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50	Closed	-$3.42K	–	451
2024 Q2	$3.42K	Buy	+50	New	+$3.47K	﹤0.01%	332
2023 Q2	–	Sell	-151	Closed	-$8.18K	–	634
2023 Q1	$8.18K	Hold	151	–	–	﹤0.01%	460
2022 Q4	$7.99K	Sell	151 -10	-6%	-$501	﹤0.01%	471
2022 Q3	$7K	Hold	161	–	–	﹤0.01%	509
2022 Q2	$9K	Buy	161 +44	+38%	+$2.5K	﹤0.01%	429
2022 Q1	$7K	Buy	117 +5	+4%	+$260	﹤0.01%	439
2021 Q4	$6K	Buy	+112	New	+$4.71K	﹤0.01%	401

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Itau Unibanco Holding S.A.'s ITCI Position: Q3 2024 in Review

Itau Unibanco Holding S.A. sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 50 shares — an estimated $3.42K sold.

Itau Unibanco Holding S.A. first reported a position in ITCI in Q4 2021 and held it in 7 quarters. The position peaked at $9K in Q2 2022. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Itau Unibanco Holding S.A. reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 50 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $3.42K.
Itau Unibanco Holding S.A. first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 7 quarters.
Itau Unibanco Holding S.A.'s Intra-Cellular Therapies Inc. position peaked at $9K in Q2 2022.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2024, filed 14 Nov 2024.